TRINETRA › Sectors › Healthcare
Concord Biotech Limited (CONCORDBIO) — share price, P/E and fundamentals
Concord Biotech Limited (NSE: CONCORDBIO) closed at ₹1,245.60 on 30 Oct 2026, -18.6% over one year, against a 52-week range of ₹987.00 – ₹1,615.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 27 Oct 2026) it reported revenue of ₹309 cr and net profit of ₹71 cr, a 22.9% net margin; revenue grew 25.1% and profit grew 15.3% year on year.
On four consecutive filed quarters its trailing P/E is 46.1; since 29 May 2025 its own P/E has ranged from 31.2 to 60.8 (median 46.0), and today's reading is higher than 52% of those 351 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 13.6%, ROCE 18.1%, debt-to-equity 0.00, Piotroski F-score 8 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 82% of 63 sector peers; PBT margin higher than 87% of 63 sector peers; ROE higher than 48% of 63 sector peers.
Key figures
| Last close | ₹1,245.60 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -15.8% / +22.6% / -18.6% |
| 52-week low – high | ₹987.00 – ₹1,615.00 |
| Market capitalisation | ₹13,031 cr |
| Trailing P/E | 46.1 |
| Price / book | 6.28 |
| EV / EBITDA | 29.0 |
| Earnings yield | 2.2% |
| TTM EPS | ₹27.00 |
| TTM net profit | ₹282 cr |
| Quarter revenue | ₹309 cr |
| Quarter net profit | ₹71 cr |
| Net margin | 22.9% |
| Revenue growth (YoY) | +25.1% |
| Profit growth (YoY) | +15.3% |
| Return on equity | 13.6% |
| ROCE | 18.1% |
| Debt / equity | 0.00 |
| Current ratio | 6.40 |
| Free cash flow | ₹108 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹15.4 cr |
Against Healthcare peers
| Metric | CONCORDBIO | Peer median | Percentile |
|---|---|---|---|
| Net margin | 22.86 | 12.67 | 83 |
| PBT margin | 31.11 | 17.57 | 87 |
| ROE | 13.61 | 13.87 | 48 |
| ROCE | 18.10 | 16.59 | 57 |
| Debt / equity | 0.00 | 0.11 | 12 |
| FCF margin | 19.10 | -0.87 | 79 |
| Cash conversion | 1.32 | 1.25 | 54 |
| Trailing P/E | 46.14 | 43.07 | 54 |
Questions
What is the P/E ratio of Concord Biotech Limited?
Concord Biotech Limited's trailing P/E is 46.1, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 29 May 2025 its P/E has ranged 31.2–60.8.
What were Concord Biotech Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Concord Biotech Limited reported revenue of ₹309 cr and net profit of ₹71 cr (consolidated), filed with the exchange on 27 Oct 2026.
What is Concord Biotech Limited's ROE?
Return on equity is 13.6% based on the balance sheet dated 30 Sept 2026.
Does Concord Biotech Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 30 Sept 2026.
What is CONCORDBIO's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, CONCORDBIO traded between ₹987.00 and ₹1,615.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.